Patient-Reported Outcomes in Oncology: The Jakafi and Zytiga Exceptions
This article was originally published in RPM Report
Oncology is the biggest area of biopharmaceutical R&D where patient-reported outcomes are not routinely collected during clinical trials. There are some good reasons why. Jakafi and Zytiga remain outliers oncology treatment with a PRO in the approved label.